Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Financial Officer of Prime Medicine, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024, at 4:30 p.m. ET in New York, NY.
马萨诸塞州剑桥，2024年5月13日（GLOBE NEWSWIRE）——致力于提供新一类差异化一次性治疗遗传疗法的生物技术公司Prime Medicine, Inc.（纳斯达克股票代码：PRME）今天宣布，Prime Medicine首席财务官艾伦·雷恩医学博士将参加2024年5月20日星期一在纳斯达克举行的H.C. Wainwright第二届年度BioConnect投资者大会的炉边谈话，美国东部时间下午 4:30，纽约州纽约。
A live audio webcast of the fireside chat will be available under "Events & Presentations" in the News & Events section of the Company's website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days following the presentation.
炉边谈话的网络直播将在公司网站新闻与事件栏目的 “活动与演讲” 下提供 www.primemedicine.com。 网络直播的重播将在演讲结束后的90天内在Prime Medicine网站上播出。
About Prime Medicine
关于普瑞米医学
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing's versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine 是一家领先的生物技术公司，致力于为患者创造和提供下一代基因编辑疗法。该公司正在部署其专有的Prime Editing平台，这是一种多功能、精确和高效的基因编辑技术，以开发一类新的差异化一次性治疗遗传疗法。Prime Editors旨在仅在基因的正确位置进行正确的编辑，同时最大限度地减少不必要的DNA修改，它有可能修复几乎所有类型的基因突变，并适用于许多不同的组织、器官和细胞类型。总而言之，Prime Editing的多功能基因编辑能力可以为数千种潜在适应症开启机会。
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around core areas of focus: hematology and immunology, liver, lung, ocular and neuromuscular. Across each core area, Prime Medicine's initial focus is on genetic diseases with a fast, direct path to treating patients, and those with high unmet need not currently addressable using other gene editing approaches. Over time, the Company intends to maximize Prime Editing's broad and versatile therapeutic potential to expand beyond the genetic diseases in its initial pipeline, potentially including immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
Prime Medicine目前正在推进围绕核心重点领域组织的多元化研究性治疗项目组合：血液学和免疫学、肝脏、肺部、眼部和神经肌肉学。在每个核心领域，Prime Medicine最初的重点是遗传性疾病，为患者提供快速、直接的治疗途径，而那些未得到满足的患者目前无法使用其他基因编辑方法来解决的需求。随着时间的推移，该公司打算最大限度地发挥Prime Editing广泛而多功能的治疗潜力，将业务扩展到其最初研发的遗传疾病之外，可能包括免疫疾病、癌症、传染病，并针对共同影响数百万人的常见疾病中的遗传风险因素。欲了解更多信息，请访问 www.primemedicine.com.
2024 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
2024 Prime Medicine, Inc. 版权所有。PRIME MEDICINE、Prime Medicine 徽标和 PASSIGE 是 Prime Medicine, Inc. 的商标。此处提及的所有其他商标均为其各自所有者的财产。
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
投资者联系人
汉娜·德雷西维奇
斯特恩投资者关系有限公司
212-362-1200
hannah.deresiewicz@sternir.com
Media Contact
Dan Budwick, 1AB
dan@1ABmedia.com
媒体联系人
丹·布德威克，1AB
dan@1ABmedia.com
译文内容由第三方软件翻译。